Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa

Pharmacotherapy

Volumn 36, Issue 10, 2016, Pages e154-e159

  Vickery, Stephen B ^a   McClain, David ^a   Wargo, Kurt A ^b  

^a Mission Health System   (United States)

^b WINGATE UNIVERSITY   (United States)

Author keywords

antibiotics; bacterial infection; Ceftolozane tazobactam; cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

AZITHROMYCIN; AZTREONAM; CEFEPIME; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; DORNASE ALFA; FLUTICASONE; IPRATROPIUM BROMIDE; IVACAFTOR; PANCRELIPASE; PREDNISONE; SALBUTAMOL; SALMETEROL; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; CASE REPORT; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG WITHDRAWAL; HOSPITAL ADMISSION; HUMAN; MALE; OFF LABEL DRUG USE; PSEUDOMONAS INFECTION; SPUTUM CULTURE; TREATMENT RESPONSE;

EID: 84990849773     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1825     Document Type: Article

References (21)

1. Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680–9.
2. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802–8.
3. Grossman S, Grossman LC. Pathophysiology of cystic fibrosis. Crit Care Nurs Q 2005;25(4):46–51.
4. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: management. Thorax 2008;63(2):180–4.
5. Goss CH, Burns JL. Exacerbations in cystic fibrosis: epidemiology and pathogenesis. Thorax 2007;62:360–7.
6. Cluck D, Lewis P, Stayer B, Spivey J, Moorman J. Ceftolozane-tazobactam: a new-generation cephalosporin. Am J Health Syst Pharm 2015;72:2135–46.
7. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-Lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 2013;74(1):31–51.
8. Tato M, García-Castillo M, Bofarull A, Cantón R. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study. Int J Antimicrob Agents 2015;46(5):502–10.
9. Zerbaxa (ceftolozane and tazobactam) package insert. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2015.
10. CLSI. Performance standards for antimicrobial susceptibility testing, 26th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
11. ClinicalTrials.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). Available from https://clinicaltrials.gov/ct2/show/NCT02070757. Accessed March 7, 2016.
12. Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2015;61(5):853–5.
13. Zamorano L, Juan C, Fernandez-Olmos A, Ge Y, Cantón R, Oliver A. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect 2010;16:1482–7.
14. Kuti JL, Pettit RS, Neu N, et al. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis 2015;83(1):53–5.
15. ClinicalTrials.gov Population pharmacokinetics and safety of intravenous ceftolozane/tazobactam in adult cystic fibrosis patients. Available from https://clinicaltrials.gov/ct2/show/NCT02421120. Accessed December 20, 2015.
16. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;43:1116–23.
17. Kuti JL, Moss KM, Nicolau DP, Knauft RF. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 2004;24(11):1641–5.
18. Wolter DJ, Acquazzino D, Goering RV, Sammut P, Khalaf N, Hanson ND. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy. Clin Infect Dis 2008;46:e137–41.
19. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012). Antimicrob Agents Chemother 2013;57(12):6305–10.
20. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 2014;43:533–9.
21. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999;115:19S–23S.